Can BPC-157 cause cancer?
Cancer risk in people is unmeasured in the cited sources: the systematic review found no clinical safety data at all.
Gastric pentadecapeptideUpdated
Short answer
Cancer risk in people is unmeasured in the cited sources: the systematic review found no clinical safety data at all.[1]
The same review notes the peptide acts on pathways involved in angiogenesis, which is the basis of the theoretical concern.[1]
The published concern and the reply
A reply from authors working on this peptide says another review speculated that angiogenesis could lead toward tumour formation, and they reject that.[2]
The same group reports anti-tumour potential in animal and cell experiments; this is their own claim, not an independent or human result.[2]
More questions on BPC-157
More on BPC-157
Sources
- 1Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
- 2Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.Pharmaceuticals (Basel, Switzerland) · 2025PMID 40573323Accessed 11 Oct 2026
Found an error? Report a correction.